Cardiac Biotech Solutions Inc. (CBSC)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cardiac Biotech Solutions Inc. (CBSC) with AI Score 48/100 (Weak). Cardiac Biotech Solutions Inc. focuses on ambulatory non-invasive cardiac monitoring. The company provides FDA and CE cleared EKG devices, cloud-based software, and smartphone apps. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026Cardiac Biotech Solutions Inc. (CBSC) Healthcare & Pipeline Overview
Cardiac Biotech Solutions Inc. delivers ambulatory non-invasive cardiac monitoring solutions, including FDA and CE cleared EKG devices and interactive software. Operating in the medical instruments and supplies sector, the company aims to improve patient compliance and provide accurate data to physicians through its international subsidiaries and My-Cardia (USA), Inc.
Investment Thesis
Cardiac Biotech Solutions Inc. presents a focused investment opportunity within the ambulatory cardiac monitoring space. With FDA and CE cleared EKG devices, the company addresses a critical need for remote and continuous cardiac monitoring. Key value drivers include the potential for increased adoption of its cloud-based software and smartphone apps, which enhance patient compliance and data accuracy. The company's gross margin stands at 43.3%. Growth catalysts include expanding its market reach through international subsidiaries and strategic partnerships. Potential risks involve competition from established players and the need for continuous innovation to maintain a competitive edge. The company's small size (5 employees) and OTC market listing introduce additional volatility and liquidity concerns. The negative P/E ratio of -3.60 and profit margin of -1767.1% indicate current financial challenges that require careful monitoring.
Based on FMP financials and quantitative analysis
Key Highlights
- FDA and CE cleared EKG devices provide a regulatory advantage in the ambulatory cardiac monitoring market.
- Gross margin of 43.3% indicates potential for profitability with increased sales volume.
- International subsidiaries enable market expansion and diversification of revenue streams.
- Cloud-based acquisition software and smartphone apps enhance patient compliance and data accessibility.
- My-Cardia (USA), Inc. subsidiary focuses on developing long-term ECG recording devices for ambulatory settings.
Competitors & Peers
Strengths
- FDA and CE cleared EKG devices.
- Interactive cloud-based acquisition software.
- Smartphone apps for iOS and Android platforms.
- Wholly-owned U.S. subsidiary, My-Cardia (USA), Inc.
Weaknesses
- Small company size (5 employees).
- Negative P/E ratio and profit margin.
- OTC market listing with potential liquidity concerns.
- Limited brand recognition compared to larger competitors.
Catalysts
- Upcoming: Potential partnerships with hospitals and clinics to expand market reach.
- Upcoming: Development and launch of advanced AI-powered diagnostic tools.
- Ongoing: Expansion into new geographic markets through international subsidiaries.
- Ongoing: Increasing adoption of remote patient monitoring solutions in geriatric care.
Risks
- Potential: Competition from established players in the cardiac monitoring market.
- Potential: Regulatory changes and compliance requirements.
- Potential: Technological advancements that could render existing products obsolete.
- Ongoing: Limited financial disclosure and transparency due to OTC listing.
- Ongoing: Negative P/E ratio and profit margin indicating financial challenges.
Growth Opportunities
- Expanding market reach through strategic partnerships: Cardiac Biotech Solutions Inc. can leverage partnerships with hospitals, clinics, and telehealth providers to expand its market reach and increase adoption of its cardiac monitoring solutions. The global telehealth market is projected to reach $55.6 billion by 2027, presenting a significant opportunity for CBSC to integrate its technology into remote patient care platforms. Timeline: Ongoing.
- Developing advanced AI-powered diagnostic tools: Integrating artificial intelligence (AI) and machine learning (ML) algorithms into its cloud-based software can enhance the accuracy and efficiency of cardiac data analysis. The AI in healthcare market is expected to reach $34 billion by 2025, driven by the need for improved diagnostics and personalized treatment plans. CBSC can leverage AI to identify subtle patterns and anomalies in ECG data, providing physicians with valuable insights. Timeline: 1-2 years.
- Focusing on geriatric care and remote monitoring: The aging population and the increasing prevalence of chronic diseases are driving the demand for remote patient monitoring solutions, particularly in geriatric care. Cardiac Biotech Solutions Inc. can tailor its products and services to meet the specific needs of elderly patients, such as ease of use and remote data transmission. The geriatric care market is projected to reach $1.04 trillion by 2028. Timeline: Ongoing.
- Entering new geographic markets through international subsidiaries: Cardiac Biotech Solutions Inc. can leverage its international subsidiaries to expand its presence in emerging markets with high growth potential. These markets often have a greater need for affordable and accessible cardiac monitoring solutions. The Asia-Pacific medical device market is expected to grow at a CAGR of 8.8% from 2021 to 2028, presenting a significant opportunity for CBSC to establish a foothold in the region. Timeline: 2-3 years.
- Enhancing mobile app functionality and user experience: Improving the functionality and user experience of its iOS and Android apps can drive greater patient engagement and compliance. This includes features such as personalized reminders, educational content, and seamless data sharing with healthcare providers. The mobile health (mHealth) market is projected to reach $254 billion by 2026, driven by the increasing adoption of smartphones and the growing demand for remote healthcare services. Timeline: 6-12 months.
Opportunities
- Expanding market reach through strategic partnerships.
- Developing advanced AI-powered diagnostic tools.
- Focusing on geriatric care and remote monitoring.
- Entering new geographic markets through international subsidiaries.
Threats
- Competition from established players in the cardiac monitoring market.
- Regulatory changes and compliance requirements.
- Technological advancements that could render existing products obsolete.
- Economic downturns that could reduce healthcare spending.
Competitive Advantages
- FDA and CE clearances provide a regulatory barrier to entry.
- Proprietary cloud-based software and mobile apps offer a differentiated solution.
- Established international subsidiaries provide a global distribution network.
About CBSC
Cardiac Biotech Solutions Inc. (CBSC) operates in the ambulatory non-invasive cardiac monitoring sector, providing products and services through its international subsidiaries. The company's core offerings include FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps compatible with both iOS and Android platforms. These solutions are designed to improve patient compliance for individuals at risk of abnormal heart rhythms and to provide physicians with more accurate diagnostic information. CBSC's wholly-owned U.S. subsidiary, My-Cardia (USA), Inc., is responsible for developing ECG recording devices that patients can wear in an ambulatory setting for up to 30 days. Cardiac Biotech Solutions Inc. focuses on innovation in the cardiac monitoring space, leveraging technology to enhance the accuracy and accessibility of diagnostic tools. The company's solutions cater to the growing need for remote patient monitoring and aim to streamline the process of cardiac data acquisition and analysis. With a focus on ambulatory settings, CBSC's products are designed to provide continuous monitoring without requiring patients to be confined to a hospital or clinic. The company's international presence allows it to serve a diverse range of markets and adapt its offerings to meet specific regional requirements. By combining hardware, software, and mobile applications, Cardiac Biotech Solutions Inc. seeks to offer a comprehensive solution for cardiac monitoring and diagnostics.
What They Do
- Develops and markets ambulatory non-invasive cardiac monitoring devices.
- Offers FDA and CE cleared EKG devices for accurate heart rhythm monitoring.
- Provides interactive cloud-based software for data acquisition and analysis.
- Creates smartphone apps for iOS and Android platforms to enhance patient compliance.
- Develops ECG recording devices worn by patients for up to 30 days.
- Offers solutions for remote patient monitoring in ambulatory settings.
- Focuses on improving the accuracy and accessibility of cardiac diagnostic tools.
Business Model
- Sells EKG devices and related hardware to healthcare providers and patients.
- Offers subscription-based access to its cloud-based software platform.
- Generates revenue through international subsidiaries in various markets.
Industry Context
Cardiac Biotech Solutions Inc. operates within the medical instruments and supplies industry, which is experiencing growth due to the increasing prevalence of cardiovascular diseases and the demand for remote patient monitoring solutions. The market is competitive, with established players like CPIVF (CardioComm Solutions Inc.) and emerging companies vying for market share. Trends include the integration of AI and machine learning for improved diagnostics and the development of wearable devices for continuous monitoring. Cardiac Biotech Solutions Inc. aims to differentiate itself through its integrated hardware, software, and mobile app solutions.
Key Customers
- Hospitals and clinics that require cardiac monitoring solutions.
- Physicians who need accurate data for diagnosing heart rhythm abnormalities.
- Patients at risk of abnormal heart rhythms who need remote monitoring.
- Telehealth providers seeking to integrate cardiac monitoring into their services.
Financials
Chart & Info
Cardiac Biotech Solutions Inc. (CBSC) stock price: Price data unavailable
Latest News
No recent news available for CBSC.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CBSC.
Price Targets
Wall Street price target analysis for CBSC.
MoonshotScore
What does this score mean?
The MoonshotScore rates CBSC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Charles K. Martin
CEO
Charles K. Martin is the CEO of Cardiac Biotech Solutions Inc., leading a team of 5 employees. His background includes experience in managing and growing small businesses, with a focus on healthcare technology. He has a proven track record of driving innovation and expanding market reach. Martin's expertise lies in identifying emerging trends and developing solutions that address unmet needs in the cardiac monitoring space. His leadership is focused on building a strong team and fostering a culture of innovation and customer focus.
Track Record: Under Charles K. Martin's leadership, Cardiac Biotech Solutions Inc. has achieved FDA and CE clearance for its EKG devices and launched its cloud-based software and smartphone apps. He has overseen the expansion of the company's international subsidiaries and the development of the My-Cardia (USA), Inc. subsidiary. Martin has also focused on building strategic partnerships to expand the company's market reach and increase adoption of its solutions.
CBSC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cardiac Biotech Solutions Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited operating history, minimal assets, or may be undergoing financial distress. Investing in OTC Other stocks carries a higher degree of risk due to the lack of regulatory oversight and the potential for fraud or manipulation. These companies may not be required to file regular financial reports with the SEC, making it difficult for investors to assess their financial health and performance.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for price manipulation and fraud.
- Higher volatility and lower liquidity compared to exchange-listed stocks.
- Lack of regulatory oversight and investor protection.
- Going concern risk due to negative P/E ratio and profit margin.
- Verify the company's financial statements and audit reports.
- Research the background and experience of the management team.
- Assess the company's competitive position and market share.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory filings.
- Check for any history of fraud or misconduct.
- Understand the risks associated with investing in OTC stocks.
- FDA and CE clearances for EKG devices.
- Development of cloud-based software and smartphone apps.
- Establishment of international subsidiaries.
- Focus on innovation in the cardiac monitoring space.
What Investors Ask About Cardiac Biotech Solutions Inc. (CBSC)
What does Cardiac Biotech Solutions Inc. do?
Cardiac Biotech Solutions Inc. specializes in developing and marketing ambulatory non-invasive cardiac monitoring solutions. The company's core offerings include FDA and CE cleared EKG devices, interactive cloud-based software, and smartphone apps designed to improve patient compliance and provide accurate data to physicians. Through its U.S. subsidiary, My-Cardia (USA), Inc., CBSC develops ECG recording devices worn by patients for up to 30 days, enabling continuous monitoring in ambulatory settings. The company aims to enhance the accuracy and accessibility of cardiac diagnostic tools, catering to the growing demand for remote patient monitoring solutions.
What do analysts say about CBSC stock?
As of 2026-03-18, there is no available analyst coverage for Cardiac Biotech Solutions Inc. due to its OTC listing and small market capitalization. Key valuation metrics include a negative P/E ratio of -3.60 and a profit margin of -1767.1%, indicating current financial challenges. Growth considerations include the potential for increased adoption of its cardiac monitoring solutions and expansion into new markets. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks before making any investment decisions.
What are the main risks for CBSC?
Cardiac Biotech Solutions Inc. faces several risks, including competition from established players in the cardiac monitoring market, regulatory changes and compliance requirements, and technological advancements that could render existing products obsolete. The company's OTC listing presents additional risks, such as limited financial disclosure, potential for price manipulation, and lower liquidity. The negative P/E ratio and profit margin indicate financial challenges that could impact the company's ability to sustain operations and invest in future growth. Investors should carefully consider these risks before investing in CBSC.
What are the key factors to evaluate for CBSC?
Cardiac Biotech Solutions Inc. (CBSC) currently holds an AI score of 48/100, indicating low score. Key strength: FDA and CE cleared EKG devices.. Primary risk to monitor: Potential: Competition from established players in the cardiac monitoring market.. This is not financial advice.
How frequently does CBSC data refresh on this page?
CBSC prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CBSC's recent stock price performance?
Recent price movement in Cardiac Biotech Solutions Inc. (CBSC) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: FDA and CE cleared EKG devices.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CBSC overvalued or undervalued right now?
Determining whether Cardiac Biotech Solutions Inc. (CBSC) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CBSC?
Before investing in Cardiac Biotech Solutions Inc. (CBSC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may not be fully up-to-date.